https://www.nasdaq.com/press-release/arrowhead-initiates-project-to-build-new-manufacturing-and-lab-facilities-2021-12-20
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-0
https://www.nasdaq.com/press-release/direxion-launches-mrna-etf-msgr-2021-12-09
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2021-conferences-2021
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-2021-year-end-results-2021-11-22
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-enters-exclusive-license-agreement-with-gsk-for-aro-hsd
https://www.nasdaq.com/press-release/arrowhead-announces-jnj-75220795-in-development-for-nash-2021-11-17
https://www.nasdaq.com/press-release/arrowhead-collaborator-presents-phase-2b-clinical-data-from-reef-1-study-in-patients
https://www.nasdaq.com/press-release/arrowhead-presents-new-clinical-data-on-aro-apoc3-at-aha-2021-2021-11-15
https://www.nasdaq.com/press-release/arrowhead-presents-additional-clinical-data-on-investigational-aro-hsd-treatment-at
https://www.nasdaq.com/press-release/arrowhead-presents-additional-clinical-data-on-investigational-aro-aat-treatment-at
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2021-year-end-results-2021-11-01
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-november-2021-conferences-2021
https://www.nasdaq.com/press-release/arrowhead-files-for-regulatory-clearance-to-begin-phase-1-2a-study-of-aro-c3-for
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-host-key-opinion-leader-webinar-on-aro-c3-for-treatment
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-initiates-phase-2b-study-of-aro-apoc3-for-treatment-of
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-october-2021-conferences-2021-09
https://www.nasdaq.com/press-release/arrowhead-earns-%2410-million-phase-1-milestone-payment-2021-09-28
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-september-2021-conferences-2021
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-2021-third-quarter-results-2021-08-05
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-receives-breakthrough-therapy-designation-from-u.s.-fda-for
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2021-third-quarter-results-2021-07-14
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4
https://www.nasdaq.com/press-release/arrowhead-announces-positive-interim-results-from-phase-1b-study-of-aro-hif2-for
https://www.nasdaq.com/press-release/arrowhead-pauses-aro-enac-phase-1-2-clinical-study-2021-07-02
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-initiates-phase-2b-study-of-investigational-aro-ang3-for
https://www.nasdaq.com/press-release/arrowhead-presents-additional-clinical-data-on-investigational-aro-aat-treatment-in
https://www.nasdaq.com/press-release/arrowhead-presents-preclinical-data-on-aro-dux4-at-fshd-society-international
https://www.nasdaq.com/press-release/arrowhead-presents-positive-interim-clinical-data-on-aro-hsd-treatment-in-patients
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-and-horizon-therapeutics-announce-collaboration-to-develop
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-initiates-phase-2b-study-of-investigational-aro-apoc3-for
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-conferences-2021-06-02
https://www.nasdaq.com/press-release/arrowhead-earns-%2410-million-option-exercise-fee-2021-05-18
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-conferences-2021-05-12
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-2021-second-quarter-results-2021-05-04
https://www.nasdaq.com/press-release/arrowhead-announces-improvement-in-fibrosis-after-aro-aat-treatment-in-patients-with
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2021-second-quarter-results-2021-04-16
https://www.nasdaq.com/press-release/arrowhead-announces-aro-dux4-as-first-muscle-targeted-rnai-candidate-using-trimtm
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-files-ind-to-begin-phase-2b-study-of-aro-apoc3-in-patients
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-2021-first-quarter-results-2021-02-04
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-files-ind-for-phase-2b-study-of-aro-ang3-for-treatment-of
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2021-first-quarter-results-2021-01-19
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-marketplace-rule-4
https://www.nasdaq.com/press-release/neubase-therapeutics-announces-appointment-of-curt-bradshaw-ph.d.-as-chief-scientific
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-conferences-2020-11-30
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-announces-closing-of-agreement-with-takeda-2020-11-25
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-2020-year-end-results-2020-11-23
https://www.nasdaq.com/press-release/arrowhead-presents-new-clinical-data-on-cardiometabolic-pipeline-at-aha-2020-2020-11
https://www.nasdaq.com/press-release/arrowhead-interim-clinical-data-demonstrate-aro-aat-treatment-improved-multiple
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-conferences-2020-11-09
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-host-key-opinion-leader-webinars-on-cardiometabolic
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2020-year-end-results-2020-11-02
https://www.nasdaq.com/press-release/takeda-and-arrowhead-collaborate-to-co-develop-and-co-commercialize-aro-aat-for-alpha
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-investor-conference-2020-09-30
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-marketplace-rule-3
https://www.nasdaq.com/press-release/arrowhead-aro-aat-phase-2-interim-results-in-patients-with-alpha-1-liver-disease
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-september-2020-conferences-2020
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-appoints-oye-olukotun-to-board-of-directors-2020-09-08
https://www.nasdaq.com/press-release/arrowhead-presents-positive-new-phase-1-2-clinical-data-on-cardiometabolic-candidates
https://www.nasdaq.com/press-release/arrowhead-and-collaborator-janssen-present-phase-2-clinical-data-on-investigational
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-august-2020-conferences-2020-08
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-initiates-phase-1b-study-of-aro-hif2-for-treatment-of-clear
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-initiates-dosing-phase-1-2-study-of-aro-enac-for-treatment
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-2020-third-quarter-results-2020-08-05
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-earns-%2420-million-milestone-payment-from-amgen-for-start-of
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-hosts-key-opinion-leader-webinar-on-aro-enac-for-treatment
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-marketplace-rule-2
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-host-key-opinion-leader-webinar-on-aro-enac-for
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2020-third-quarter-results-2020-07-08
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-june-2020-conferences-2020-05-28
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-2020-second-quarter-results-2020-05-07
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-may-2020-conferences-2020-05-01
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-announces-retirement-of-coo-bruce-given-2020-05-01
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2020-second-quarter-results-2020-04-22
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-files-for-regulatory-clearance-to-begin-phase-1-2a-study-of
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-marketplace-rule-1
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-announces-precautionary-measures-to-mitigate-effects-of
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-initiates-phase-1-2-study-of-aro-hsd-in-normal-healthy
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-march-2020-conferences-2020-03
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-2020-first-quarter-results-2020-02-05
https://www.nasdaq.com/press-release/arrowhead-reports-interim-clinical-data-on-cardiometabolic-candidates-aro-apoc3-and
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2020-first-quarter-results-2020-01-22
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-appoints-james-hassard-as-chief-commercial-officer-2020-01
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-doses-first-patient-in-aroaat2002-open-label-phase-2-study
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-inducement-grants-under-nasdaq-marketplace-rule-0
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-files-for-regulatory-clearance-to-begin-phase-1-study-of
https://www.nasdaq.com/press-release/live-nation-entertainment-zebra-technologies-steris-set-to-join-sp-500-others-to-join
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-appoints-marianne-de-backer-to-board-of-directors-2019-12
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-files-ind-for-phase-1b-study-of-aro-hif2-for-treatment-of
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-closes-underwritten-public-offering-with-gross-proceeds-of-
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-announces-pricing-of-underwritten-public-offering-of-common
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-announces-proposed-underwritten-offering-of-common-stock
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-participate-in-upcoming-december-2019-conferences-2019
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-reports-fiscal-year-2019-results-2019-11-25
https://www.nasdaq.com/press-release/arrowhead-presents-new-clinical-data-on-cardiometabolic-candidates-aro-apoc3-and-aro
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-announces-planned-management-transition-2019-11-15
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-to-webcast-fiscal-2019-year-end-results-2019-11-11
https://www.nasdaq.com/press-release/arrowhead-and-collaborator-janssen-present-phase-2-clinical-data-for-investigational
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-presents-preclinical-data-on-aro-enac-at-the-north-american
https://www.nasdaq.com/press-release/arrowhead-pharmaceuticals-hosts-rd-day-on-emerging-pipeline-of-rnai-therapeutics-2019
